MX2017001863A - Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. - Google Patents
Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.Info
- Publication number
- MX2017001863A MX2017001863A MX2017001863A MX2017001863A MX2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A MX 2017001863 A MX2017001863 A MX 2017001863A
- Authority
- MX
- Mexico
- Prior art keywords
- glucocorticoid
- neovascularization
- prevention
- allograft rejection
- loaded nanoparticles
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 206010029113 Neovascularisation Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 abstract 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 abstract 3
- 206010011017 Corneal graft rejection Diseases 0.000 abstract 1
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000000159 corneal neovascularization Diseases 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037000P | 2014-08-13 | 2014-08-13 | |
| US201562139561P | 2015-03-27 | 2015-03-27 | |
| PCT/US2015/043478 WO2016025215A1 (en) | 2014-08-13 | 2015-08-03 | Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001863A true MX2017001863A (es) | 2017-07-17 |
Family
ID=54011072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001863A MX2017001863A (es) | 2014-08-13 | 2015-08-03 | Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10195212B2 (enExample) |
| EP (1) | EP3193827A1 (enExample) |
| JP (1) | JP2017524712A (enExample) |
| KR (1) | KR20170046146A (enExample) |
| CN (1) | CN106794152A (enExample) |
| CA (1) | CA2957764C (enExample) |
| MX (1) | MX2017001863A (enExample) |
| WO (1) | WO2016025215A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| US10398742B2 (en) | 2014-12-15 | 2019-09-03 | The Johns Hopkins University | CVS transplantation for treatment of bacterial vaginosis |
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| EP3250184B1 (en) | 2015-01-27 | 2024-12-18 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| MX2018003462A (es) | 2015-09-22 | 2018-09-06 | Graybug Vision Inc | Compuestos y composiciones para el tratamiento de trastornos oculares. |
| KR20180102069A (ko) | 2015-11-12 | 2018-09-14 | 그레이버그 비젼, 인크. | 요법을 위한 응집성 마이크로입자 |
| DE102017002454A1 (de) * | 2017-03-14 | 2018-09-20 | Friedrich-Schiller-Universität Jena | Organische Polymerpartikel enthaltend Poly(oxazolin)-Stabilisatoren und Verwendung von Poly(oxazolinen) zur Stabilisierung von organischen Polymerpartikeln |
| MX2019011242A (es) | 2017-03-23 | 2020-01-21 | Graybug Vision Inc | Farmacos y composiciones para el tratamiento de trastornos oculares. |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| WO2019071275A1 (en) * | 2017-10-06 | 2019-04-11 | Aciont Inc. | DEVICES FOR DELIVERY OF NON-INVASIVE OCULAR MEDICINE |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| WO2021168239A1 (en) * | 2020-02-21 | 2021-08-26 | The Johns Hopkins University | Suprachoroidal delivery of drug particles to reduce toxicity |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
| US4888176A (en) | 1984-05-21 | 1989-12-19 | Massachusetts Institute Of Technology | Controlled drug delivery high molecular weight polyanhydrides |
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US4789724A (en) | 1986-10-17 | 1988-12-06 | Massachusetts Institute Of Technology | Preparation of anhydride copolymers |
| US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| AU2004224530A1 (en) * | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targenting drug delivery and sustained drug release |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20050226814A1 (en) | 2004-04-13 | 2005-10-13 | Bausch & Lomb Incorporated | Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid |
| US20060089590A1 (en) * | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
| JP2007001926A (ja) * | 2005-06-24 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 吸入・噴霧用ステロイド製剤 |
| WO2007074604A1 (ja) * | 2005-12-26 | 2007-07-05 | Ltt Bio-Pharma Co., Ltd. | 水溶性非ペプチド性低分子薬物含有ナノ粒子 |
| WO2008139804A1 (ja) * | 2007-05-14 | 2008-11-20 | Ltt Bio-Pharma Co., Ltd. | 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子 |
| WO2009108626A2 (en) * | 2008-02-25 | 2009-09-03 | Eyegate Pharma S.A.S. | Enhanced delivery of a therapeutic to ocular tissues through iontophoresis |
| US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| WO2011041373A1 (en) | 2009-09-29 | 2011-04-07 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| CA2845673A1 (en) | 2011-09-13 | 2013-03-21 | Altacor Limited | Pharmaceutical nanoparticle compositions |
| AU2013209452B2 (en) * | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| NZ741873A (en) * | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
-
2015
- 2015-08-03 WO PCT/US2015/043478 patent/WO2016025215A1/en not_active Ceased
- 2015-08-03 US US15/502,732 patent/US10195212B2/en active Active
- 2015-08-03 CA CA2957764A patent/CA2957764C/en active Active
- 2015-08-03 JP JP2017507390A patent/JP2017524712A/ja active Pending
- 2015-08-03 MX MX2017001863A patent/MX2017001863A/es unknown
- 2015-08-03 EP EP15756267.9A patent/EP3193827A1/en not_active Withdrawn
- 2015-08-03 CN CN201580053822.9A patent/CN106794152A/zh active Pending
- 2015-08-03 KR KR1020177006811A patent/KR20170046146A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957764A1 (en) | 2016-02-18 |
| EP3193827A1 (en) | 2017-07-26 |
| JP2017524712A (ja) | 2017-08-31 |
| KR20170046146A (ko) | 2017-04-28 |
| WO2016025215A1 (en) | 2016-02-18 |
| US20170157147A1 (en) | 2017-06-08 |
| CA2957764C (en) | 2019-07-02 |
| US10195212B2 (en) | 2019-02-05 |
| CN106794152A (zh) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001863A (es) | Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion. | |
| Ke et al. | Role of non-covalent and covalent interactions in cargo loading capacity and stability of polymeric micelles | |
| TN2014000441A1 (en) | A delayed release drug formulation | |
| MX2015012887A (es) | Composiciones de un poliortoester y un solvente aprotico. | |
| MX2016014320A (es) | Composiciones de suspension de liberacion prolongada. | |
| CO2017007003A2 (es) | Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares | |
| NZ741873A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| MX2018005971A (es) | Composicion farmaceutica novedosa que comprende particulas que comprenden un complejo de un polirribonucleotido de hebra doble y una polialquilenimina. | |
| CO2018005920A2 (es) | Composiciones y métodos para fabricar micropartículas de proteína | |
| CO2017012573A2 (es) | Formación de nanopartículas de ciclosporina a/ciclodextrina | |
| AT515178A5 (de) | Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| MX2015010083A (es) | Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos. | |
| EP3494959A3 (en) | Sustained release latanoprost implant | |
| MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
| MX390100B (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
| WO2015099985A3 (en) | Cationic materials and formulations for drug delivery | |
| WO2013013038A3 (en) | Doping agents and polymeric compositions thereof for controlled drug delivery | |
| AR095544A1 (es) | Un agente de sostén | |
| MX2017000041A (es) | Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos. | |
| MX2018012682A (es) | Conjugados de acido hialuronico y usos de los mismos. | |
| PH12016500869A1 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| FI3229776T3 (fi) | Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt | |
| PH12014502834A1 (en) | Pharmaceutical form for extended release of active substances |